OEM Mesotherapy Products: What Distributors Should Look for Before Importing

Globally, the medical aesthetics industry is shifting quickly from traditional surgery to minimally invasive procedures that involve little pain and have short recovery times. This transformation is being driven by the growing global demand for minimally invasive cosmetic treatments. According to the data, the aesthetic medicine market is expected to grow from $73.7 billion in 2025 to $80.09 billion in 2026, at a compound annual growth rate (CAGR) of 8.7%. In addition, the global mesotherapy market is projected to hit $1.5 billion by 2030, with regenerative skin boosters and complex-formula products experiencing the highest growth.

Market growth means new brands are appearing. Most of them don’t build their own manufacturing plants and use OEM services. As a result, OEM mesotherapy products have become a strategic asset that global distributors are fighting to obtain. However, the window of opportunity for market entry is shrinking, and the cost of errors in product selection is growing.

OTESALY is a specialised trading company with over 20 years of experience in exporting medical aesthetic products, dedicated to offering strictly validated mesotherapy solutions to beauty salons, plastic surgery hospitals, clinics and wholesalers. The article is a practical guide to four key dimensions: regulatory compliance, scientific rationale for core ingredients, product portfolio strategies and criteria for supplier selection.

Why PDRN Is the Central Focus of Global Sourcing?

The mesotherapy products with PDRN are moving from the “optional” items to the “essential” ones on the product lists of the global distributors. PDRN is made up of DNA fragments derived from salmon sources, and its mechanism of action has been thoroughly verified by clinical studies. It stimulates adenosine A2A receptors, promotes the proliferation and migration of fibroblasts, and stimulates the synthesis of collagen and elastin. At the same time, it increases the expression of VEGF, improves microcirculation, and accelerates tissue regeneration. 89% of subjects reported a significant improvement in skin redness and sensitivity after 6 weeks of PDRN treatment, as demonstrated by clinical data.

This ingredient has double efficacy, which makes it especially outstanding in two specific indications, namely, skin rejuvenation mesotherapy and hair growth mesotherapy. PDRN is increasingly incorporated as a core active ingredient in 'skin booster' products due to its effectiveness in skin rejuvenation, reduction of fine lines, improvement of skin texture, as well as its anti-inflammatory and moisturising effects. In the field of hair restoration, several clinical studies have demonstrated that mesotherapy treatments may significantly improve hair density in patients with androgenic alopecia.

It is however important to mention that the clinical efficacy of PDRN depends to a great extent on the purity of the raw materials, the molecular weight distribution and the concentration stability. Different suppliers have different products – which is exactly why you should focus on assessing the maturity of a mesotherapy with PDRN product line. The active formulations of OTESALY’s PDRN product series are characterised by purity and a precisely defined polynucleotide content, with comprehensive reports of third-party testing to be able to fully verify and trace the concentration and safety of every batch.

Compliance: It’s a Lock, Not a Door

The basic entry threshold into the cross-border trade of medical aesthetics products is regulatory compliance. The second risk is product returns or recalls when OEM mesotherapy products bypass compliance for the sake of cost-effectiveness.

1. ISO 13485 and GMP: The Building Blocks of Quality Systems

ISO 13485 Quality Management System certification is a prerequisite for injectable aesthetic products. All OTESALY OEM products are manufactured by ISO 13485 and GMP certified plants, with full quality control throughout the entire lifecycle from design and development to manufacturing.

2. CE and FDA: Gateways to European and U.S. Markets

In the European Union market, medical-grade mesotherapy products must be CE Marked. In the U.S. market, suppliers must provide FDA registration details or 510(k) clearance. The OTESALY PDRN injectable solutions series has full CE and FDA registration dossiers and can be directly used for compliance submissions in target markets.

3. Updates to EU MDR

In March 2026 the European Commission adopted two delegated acts enlarging the list of the "well-established technologies". This expansion, however, does not relieve manufacturers of the burden of clinical evaluation and the rigorous clinical evaluation requirements that apply. OTESALY has revised the technical documentation and post-market surveillance plans for its product lines targeting the EU, so that your supply chain is not disrupted by regulatory changes.

4. Supply Chain Visibility

Compliance is not just product certifications, it is also having a transparent supply chain. OTESALY generates Certificates of Origin, sterility test reports and full production batch records for each product batch to help you develop a traceable quality management system.

PDRN Injectable Solutions VS Traditional Formulations

PDRN injectable solutions and conventional non-crosslinked hyaluronic acid (HA) preparations have different applications in the market for regenerative mesotherapy products. They are not mutually exclusive substitutes, but rather complementary partners — a dynamic we call “Dual-Core Value.” Traditional HA is focused on short-term hydration, while PDRN is focused on long-term tissue repair.

The primary use of the use of traditional non-crosslinked HA mesotherapy solutions is hydration and moisture retention, and with their relatively controllable costs they are one of the highest-volume product categories purchased for daily operations in beauty salons and clinics. PDRN injectable solutions act at a deeper level of biological repair – activating the cells’ own intrinsic repair mechanisms, allowing tissue regeneration. This is treatment in terms of the “root cause”. Often, the combination of these two modalities leads to a situation in which the sum is greater than its parts (1+1 > 2).

Furthermore, hair growth mesotherapy is a product category which requires a separate standalone portfolio. The global demand for hair loss treatments is growing and the clinical data supporting the efficacy of PDRN in the area of hair regeneration is becoming more and more robust. OTESALY’s line of hair growth mesotherapy products also offers a variety of combined formulations with both active peptides and PDRN to address the treatment needs of patients with different types of hair loss.

A real case study: “Product Selection Upgrades” journey of One beauty salon

In mid-2023, Clinic M, a Spanish chain of aesthetic clinics with seven locations, began preparing to introduce mesotherapy as one of its key services. The consortium evaluated five potential suppliers and decided to partner with OTESALY for the long term, purchasing a complete product portfolio that included the PDRN series, a non-crosslinked HA skin booster and a mesotherapy product for hair restoration.

The logic of decision-making has mainly 3 points:

1. the product line is a complete spectrum from PDRN to HA for easier purchase of everything at one time;

2. All products have CE certification and are supported by ISO 13485 quality system assurance and meet the requirements for entry into the EU market.

3. OTESALY provides technical product documentation, clinical data support and operational training materials in Spanish.

Real Results After the Partnership

In a six-month pilot project Clinic M carried out over 300 mesotherapy procedures using products exclusively from OTESALY.

● 85% of end-clients who received facial rejuvenation treatments with Mesotherapy with PDRN (Model: OTESALY® MESO PDRN) reported significant improvement in skin firmness, radiance and appearance of fine lines after completing full course of treatment. “My skin is no longer prone to redness and my pores are much more refined – something I have never achieved with any other products I used before,” said one of the patients, a 42-year-old woman who has been struggling with rosacea for a long time, after four treatments.

● In the hair growth mesotherapy program (Model: OTESALY® H-PDRN Solution), an increase in hair density was observed in about 70% of patients with androgenic alopecia after three months. In the follow-up visit at the 12th week, trichoscopy analysis of a 35-year-old male patient revealed an increase in the number of hair follicular units per square centimetre from 105 to 138.

● Clinic M’s revenue from mesotherapy services increased by around 40% in six months, and has become its fastest growing service segment, with a customer repurchase rate of 68%.

We’ve had clinical results with the product line we brought in from OTESALY that have far exceeded our expectations', said The Procurement Manager at Clinic M. There has been a huge increase in word-of-mouth referrals from existing clients and we don’t have to manage multiple suppliers at the same time. “The after-sales support team of OTESALY provides us with the latest clinical application literature and training support regularly every quarter which is a great help to small clinics like ours without a medical research team.